Fundraising Fox

RevOpsis Therapeutics

Springfield, US · Founded 2022 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

RB
Ramanath BhandariExecutive
JO
Jeff OlsonNamed on SEC filing

Board

RP
Ram PalankiBoard director

Investors · 1

ExSight Venturesreported · 2 sourcesNew York

Funding

SEC filings, press & company announcements

$25.1M disclosed across 4 of 6 rounds · 2022–2024

  • $16.5Mseed funding roundApr 2024 · 4 sources
    Source ↗
▶$575KraisedNov 2024 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ramanath BhandariExecutive Officer
  • Ram PalankiDirector
Amount sold
$575K
Minimum investment
$25K
First sale
Oct 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedAug 2023 · 36 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Ram PalankiDirector
  • Ramanath BhandariExecutive Officer, Director
Offering amount
$7.9M
Amount sold
$7.9M
Minimum investment
$25K
First sale
Jul 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$100KraisedAug 2022 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Ramanath BhandariExecutive Officer, Director, Promoter
  • Jeff OlsonDirector
  • Ram P PalankiExecutive Officer, Director
Offering amount
$18M
Amount sold
$100K
Minimum investment
$25K
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$521KofferedJul 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ram PalankiExecutive Officer, Director
  • Jeff OlsonDirector
  • Ramanath BhandariExecutive Officer, Director, Promoter
Offering amount
$521K
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$521KofferedJun 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ramanath BhandariExecutive Officer, Director, Promoter
  • Jeff OlsonDirector
  • Ram PalankiExecutive Officer, Director
Offering amount
$521K
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

ExSight Ventures Invests in RevOpsis Therapeutics to Advance Innovative Treatments for Blinding Eye Diseasesprnewswire.com · Sep 2025RevOpsis Therapeutics Receives Investment From ExSight Venturesfinsmes.com · Sep 2025RevOpsis: $16.5 Million Raised For Developing Ophthalmic Therapiespulse2.com · Apr 2024RevOpsis raises $16.5 million to advance neovascular AMD treatment candidatehealio.com · Apr 2024RevOpsis raises $16.5M to advance nAMD tri-specific therapyglance.eyesoneyecare.com · Apr 2024RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatmentprnewswire.com · Apr 2024

Frequently asked questions

Who are RevOpsis Therapeutics's investors?
RevOpsis Therapeutics's investors include ExSight Ventures.
How much funding has RevOpsis Therapeutics raised?
RevOpsis Therapeutics has disclosed $25.1M raised across 4 of its 6 known rounds.
Where is RevOpsis Therapeutics headquartered?
RevOpsis Therapeutics is headquartered in Springfield, US.